The ESMO (European Society for Medical Oncology) 20th World Congress on Gastrointestinal Cancer came to a successful conclusion after four days of practice-changing research and education, according to the organizers.
The multidisciplinary meeting brought together nearly 3,500 participants from 90 countries, including oncologists, gastroenterologists, pathologists, surgeons, and researchers, to review the latest clinical data, engage in debate and discovery, and discuss strategies to improve the outcomes of patients with cancers of the gastrointestinal tract. The 1o countries with the most delegates were Spain, France, Switzerland, Italy, USA, Argentina, Belgium, Germany, Poland, and Japan.
Practice-changing studies presented at the 20th ESMO World Congress on Gastrointestinal Cancer included:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze